BIOPHYLAXIS
Regenerative Medicine
Α major target of BIOPHYLAXIS S.A.
This is a field aiming at the use of stem cells for replacement of congenitally dysfunctional cells in patients, or cells that have undergone irreversible damage following a disease (atherosclerotic heart disease, ischemic damage of the central nervous system (CNS), CNS trauma, hepatitis, neurodegenerative conditions including multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer’s disease, etc). Presently, together with gene therapy, the so-called "cell therapy" which focuses on regenerative medicine is a cutting-edge filed of research aimed at eventually developing new, more effective treatment for certain chronic congenital and other diseases.

Since umbilical blood stem cells (UBSC) and other stem cells as well (mesenchymal from umbilical cord, fat stem cells, etc.) can be safely stored and maintained, today’s newborn have the possibility for future use of their own cells in regenerative medicine applications. Autologous UBSC are superior compared to autologous bone marrow cells since they have increased plasticity, less cost, and can also be obtained withoutτ surgical interference. Hence the proliferation of UBSC is targeted so that following successful studies, transplantation of these cells can be safely used in regenerative medicine.

Examples of applications of cell therapy: There exist today several positive examples supporting the use of stem cells in patients; for example, patients with paralysis (quadriplegia) can obtain substantial mobility following stem cell transplantation in combination with intensive physical therapy (protocol of Dr. Carlos Lima [Lima C, et al, 2006: Olfactory mucosa autografts in human spinal cord injury: a pilot clinical study, J Spinal Cord Med. 29(3):191-203],with the collaboration of neurosurgeon, Dr. C. Gogos). Moreover in patients who suffered an ischemic heart attack (cardiac infarct) infusion of autologous stem cells was considered to assist the process of neo-vascularization of small blood vessels (diameter <10 μm: Manginas A, et al, 2007,Pilot study to evaluate the safety and feasibility of intracoronary CD133+ and CD133-CD34+ cell therapy in patients with non-viable anterior myocardial infarction. Catheter Cardiovasc Interven, 69: 773-81). Moreover, in joint trauma, infusion of autologous stem cells was suggested to help to cartilage repair, in addition to possible beneficial effects of intervertebral disc disease and rheumatoid arthritis (tissue engineering)

BIOPHYLAXIS S.A. has a major research emphasis in studies related to regenerative medicine, specifically making use of specialized peptides which enhance cell adhesion, motility, proliferation and differentiation.

Recent reviews related to stem cell use
  1. J Cell Physiol. 2010 Jan;222(1):23-32. Mesenchymal stem cells in regenerative medicine: opportunities and challenges for articular cartilage and intervertebral disc tissue engineering. Richardson SM, Hoyland JA, Mobasheri R, Csaki C, Shakibaei M, Mobasheri A.

  2. Pract Neurol. 2011 Feb;11(1):29-36. Stem cells as a resource for regenerative neurology. Connick P, Patani R, Chandran S.

  3. J Cardiovasc Pharmacol Ther. 2010 Dec;15(4):338-43. Review article: current status of myocardial regeneration: new cell sources and new strategies. Rangappa S, Makkar R, Forrester J

  4. Heart. 2012 Jan 27. [Epub ahead of print] Clinical applications of patient-specific induced pluripotent stem cells in cardiovascular medicine. Oh Y, Wei H, Ma D, Sun X, Liew R